InMode (INMD) Files ITC Complaint Against ILOODA and its U.S. Distributor, Cutera

March 16, 2021 7:36 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, has filed a complaint with the United States International Trade Commission ("ITC") alleging ILOODA's SecretRF fractional radio frequency ("RF") microneedling system, distributed in the United States by Cutera, Inc., infringes U.S. Patent No. 10,799,285. Additionally, InMode requested that the ITC initiates an investigation into ILOODA's infringing imports and issue an exclusion order to bar importation of SecretRF.

"As a disrupter in medical aesthetic devices, InMode has committed significant research and development resources to the development of its differentiated RF technologies," InMode's Chief Technology Officer, Dr. Michael Kreindel, commented. "Those efforts have led to an ever-expanding intellectual property (IP) portfolio, a fundamental component of InMode's strategic plan to grow shareholder value. InMode will continue to develop efficacious minimally invasive and hands-free treatments using its patented technology and plans to vigorously defend its IP."

Since its inception, InMode has worked tirelessly to develop state-of-the-art electro-surgical bi-polar radiofrequency devices, bringing breakthrough aesthetic and wellness procedures to the market for the face, body, and skin. Through its ongoing commitment to research and development, InMode has become an innovative leader and has pioneered full body fractional RF technology through the commercialization of the Morpheus8 Subdermal Adipose Remodeling (SARD) device.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Litigation, Management Comments